In the BioHarmony Drug Report Database

"Preview" Icon

Glasdegib

Daurismo (glasdegib) is a small molecule pharmaceutical. Glasdegib was first approved as Daurismo on 2018-11-21. It is used to treat myeloid leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. The pharmaceutical is active against smoothened homolog. Daurismo’s patent is valid until 2036-04-13 (FDA).

 

Trade Name

 

Daurismo
 

Common Name

 

glasdegib
 

ChEMBL ID

 

CHEMBL2043437
 

Indication

 

myeloid leukemia acute
 

Drug Class

 

Hedgehog signaling inhibitors

Image (chem structure or protein)

Glasdegib structure rendering